These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26363059)

  • 21. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.
    Ishibashi K; Tokumoto T; Shirakawa H; Hashimoto K; Ikuta K; Kushida N; Yanagida T; Shishido K; Aikawa K; Toma H; Inoue N; Yamaguchi O; Tanabe K; Suzutani T
    Transpl Infect Dis; 2011 Jun; 13(3):318-23. PubMed ID: 20804536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases.
    Zhong J; Khanna R
    J Clin Virol; 2009 Dec; 46 Suppl 4():S68-72. PubMed ID: 19646921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.
    Schleiss MR; Bourne N; Stroup G; Bravo FJ; Jensen NJ; Bernstein DI
    J Infect Dis; 2004 Apr; 189(8):1374-81. PubMed ID: 15073673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
    McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
    Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles.
    Curtsinger JM; Liu YN; Radeke R; Bryon MK; Fuad S; Bach FH; Gehrz RC
    J Gen Virol; 1994 Feb; 75 ( Pt 2)():301-7. PubMed ID: 8113751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T cell epitopes on gp93.
    Liu YN; Curtsinger J; Donahue PR; Klaus A; Optiz G; Cooper J; Karr RW; Bach FH; Gehrz RC
    J Gen Virol; 1993 Oct; 74 ( Pt 10)():2207-14. PubMed ID: 7691989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.
    Choi KY; El-Hamdi NS; McGregor A
    J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33729125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
    Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
    PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of gH/gL/pUL128-131 pentameric complex, gH/gL/gO trimeric complex, gB and gM/gN glycoproteins in a human cytomegalovirus using automated capillary western blots.
    Rustandi RR; Loughney JW; Shang L; Wang S; Pauley CJ; Christanti S; Kristopeit A; Culp TD
    Vaccine; 2021 Jul; 39(33):4705-4715. PubMed ID: 34229890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.
    Cui X; Freed DC; Wang D; Qiu P; Li F; Fu TM; Kauvar LM; McVoy MA
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28381568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.
    Reuter N; Kropff B; Schneiderbanger JK; Alt M; Krawczyk A; Sinzger C; Winkler TH; Britt WJ; Mach M; Thomas M
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus.
    Dasari V; Smith C; Zhong J; Scott G; Rawlinson W; Khanna R
    J Gen Virol; 2011 May; 92(Pt 5):1021-1031. PubMed ID: 21307228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium.
    Pachnio A; Ciaurriz M; Begum J; Lal N; Zuo J; Beggs A; Moss P
    PLoS Pathog; 2016 Sep; 12(9):e1005832. PubMed ID: 27606804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.
    Sabbaj S; Pass RF; Goepfert PA; Pichon S
    J Infect Dis; 2011 Jun; 203(11):1534-41. PubMed ID: 21592981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease.
    Woo PC; Lo CY; Lo SK; Siau H; Peiris JS; Wong SS; Luk WK; Chan TM; Lim WW; Yuen KY
    Clin Diagn Lab Immunol; 1997 Sep; 4(5):515-8. PubMed ID: 9302197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.
    Chiuppesi F; Wussow F; Johnson E; Bian C; Zhuo M; Rajakumar A; Barry PA; Britt WJ; Chakraborty R; Diamond DJ
    J Virol; 2015 Dec; 89(23):11884-98. PubMed ID: 26378171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
    Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
    Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.